| Oct 8 |
Merck posts late-stage trial win for Keytruda in head and neck cancer
|
| Oct 8 |
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
|
| Oct 7 |
Merck: Murky Is A Better Description - Strong Sell (Technical Analysis)
|
| Oct 7 |
Microbiotica initiates subject dosing in Phase Ib melanoma therapy trial
|
| Oct 7 |
Merck Is At Support And Should Go Higher (Technical Analysis)
|
| Oct 6 |
Merck & Co Inc. (MRK): Analysts Are Bullish On This Quality Stock Right Now
|
| Oct 4 |
Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August
|
| Oct 4 |
Should Weakness in Merck & Co., Inc.'s (NYSE:MRK) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
|
| Oct 3 |
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
|
| Oct 1 |
U.S. port strike expected to have limited impact on healthcare supply chain: HHS
|
